Prognostic Study Of The Use Of Urocline Kallikrein Within 24-72 Hours Of Onset Of Cerebral Infarction

BackgroundStroke had high attack rate,mutilation rate,recurrence rate and fatality rate which gave great burden to the family and the society.Ischemic Stroke?IS?is the most common type.At present,Evidence showed that revascularization treatment was effective,but short treatment time windows strict indications,high medical technical requirements,high medical costs and multi-disciplinary coordination limited the clinical use of revascularization treatment.Therefore,it is of great significance to explore other therapeutic strategy of Ischemic Stroke.This study was conducted to investigate the efficacy of Urocline Kallikrein in the treatment of Ischemic Stroke within 24-72 hours of onset.ObjectiveTo investigate the efficacy of Urocline Kallikrein in the treatment of Ischemic Stroke within 24-72 hours of onset.Methods1.Patients with acute cerebral infarction from October 2016 to October 2018 were randomly divided into treatment group and control group.All these subjects broke out within 24-72 hours.2.All the patients were given a basic therapy.Urocline kallidinogenase was administrated to the patients in the treatment group in addition to the basic therapy.3.The prognosis of the treatment group and the control group were evaluated and recorded in 180^th day.4.Computed Tomographic Prfusion imaging?CTP?was used to assess the low perfusion volume and core infarct volume in the lesion area.Patients with CTP in the treatment group were regrouped.The prognosis of the subgroups were evaluated and recorded in 180^th day.Results1.Urocline kallidinogenase in treatment of cerebral ischemic stroke within 24-72hours of onset is effective:NIHSS score?3.63±4.55VS5.14±6.87,P=0.042??mRS score?0.98±1.25VS1.38±1.65,P=0.032?,MMSE score?21.50±6.25VS19.62±7.32,P=0.029??see Table 2?;drug effectiveness?84.00%VS65.60%,P=0.001??see Table 3?;functional independence?88.80%VS74.40%,P=0.030??patients with normal cognitive function?78.40%VS56.80%,P=0.001??see Table 4?;stroke recurrence rate?1.60%VS6.40%,P=0.053??mortality rate?1.60%VS4.00%,p=0.443??see Table 5?.2.The drug efficacy in the subgroup who is low perfusion volume/core infarct volume ratio?2.0 were significantly better than the control group:NIHSS score?1.56±1.68VS7.82±3.03,P=0.001??mRS score 0.62±0.73VS2.09±1.74,P=0.001)?MMSE score?24.34±2.78VS15.36±5.48,P=0.001??drug effectiveness?93.10%VS36.36%,P=0.001??functional independence Sex?96.55%VS54.55%,P=0.005?and patients with normal cognitive function?62.07%VS18.18%,P=0.013??recurrence rate?0.00%VS0.09%,P=0.275??see Table 6?.Conclusions1.Urocline Kallidinogenase still showed a obvious effect when started to use within24-72 hours after Ischemic Stroke,and it is more effective,no difference between the safety.2.CTA+CTP could predict the prognosis of patients with cerebral infarction starting within 24-72 hours.